On October 21, CANSINOBIO rose 5.53% in Regular Trading, trading at HK$30.58, with turnover of HK$14.89 million.

The move coincided with a recent easing in market concerns around revisions to the biotechnology export control catalogue, which helped improve sentiment across healthcare and biotech names, while the company has also scheduled a board meeting for October 27 to review and approve its third-quarter results.

Company fundamentals have provided additional context ahead of that earnings date. CANSINOBIO previously reported first-half revenue of RMB547 million, up 46.1% year over year, while adjusted net loss narrowed to RMB721,000 and operating profit turned positive at RMB27.54 million. Separately, the company disclosed receipt of RMB2.87 million in government subsidies, equivalent to 10.28% of its most recent audited annual net profit, which it said is expected to have a positive impact on profit, subject to audit treatment.

The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.